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ABSTRACT
Objectives: Nitrogen-containing heterocyclic compounds play an important role in medicinal chemistry. Among them, five-membered ring pyrazolines 
have found to possess many biological and pharmacological activities such as anticancer, antitubercular, antimicrobial, anti-inflammatory. Objective 
is to determine the physicochemical and drug-like properties of the synthesized pyrazolines by in silico methods and to screen their antidiabetic and 
antioxidant activities.
Methods: Chalcones were synthesized from naphthaldehyde by condensing with various substituted acetophenones in ethanol and cyclized into 
pyrazolines using semicarbazides/thiosemicarbazides by conventional and microwave oven synthesis. The physicochemical and drug-like properties 
were determined using computational tools. Anti-diabetic activity was evaluated by alpha amylase inhibition assay method. Antioxidant activity 
studies were done by 2,2-diphenyl-1-picrylhydrazyl and nitric oxide method.
Results: Pyrazolines were synthesized from chalcones. Microwave irradiated synthesis of chalcone was carried out to get higher yield with less 
reaction period as compared to conventional method. The synthesized pyrazolines produce yield around 68% (conventional) and 85% (microwave). 
In silico studies showed considerable values satisfying all the parameters of physicochemical and Lipinski’s Rule of Five properties. Among the 
compounds tested for antidiabetic and antioxidant studies, some showed promising activity.
Conclusion: Physiochemical and drug-like properties revealed that these compounds have good bioavailability and drug likeness properties. Hence, 
these compounds are found to be interesting lead molecules for further synthesis as antidiabetic and antioxidant agents.
Keywords: Chalcones, Pyrazolines, In silico physicochemical properties, Biological activities.
INTRODUCTION
Pyrazoline derivatives are the electron-rich nitrogen heterocycles. 
They broadly exist in many natural alkaloids, vitamins, pigments, and 
synthetic derivatives possessing variant biological and pharmacological 
activities [1-3].
Degenerative processes related to aging and in diseases, namely, cancer, 
coronary heart disease, and Alzheimer’s disease has been resulted from 
the oxidative and free radical mediated reactions [4]. It has been focused 
on the use of synthetic antioxidants to inhibit lipid peroxidation and to 
protect from damage due to free radicals [5]. 2-pyrazolines are capable 
of preventing oxidative damage as well as clastogenic effects [6] due to 
its significant antioxidant potential.
Good drug absorption and suitable drug delivery are very important 
in the development of drugs intended for oral use. Due to poor 
pharmacokinetics, about 30% of drugs fail in the initial stage of drug 
discovery and development. Hence, to minimize these failures, proper 
understanding of molecular properties is very essential. The crucial 
role played by small heterocyclic molecules in drug design cannot be 
denied. These molecules act as highly functionalized scaffolds [7].
In this work, pyrazoline, a five-membered heterocyclic ring, a 
prominent lead molecule, has played a vital role in the development of 
different medicinal agents. A variety of methods has been reported for 
the preparation of this class of compounds. In the present article, we 
report the reaction of naphthaldehyde with different aromatic ketones 
to form pyrazolines bearing a naphthyl moiety and studied their in silico 
molecular properties and in vitro antidiabetic and antioxidant activities.
METHODS
General methods
All used materials were obtained commercially, mostly from Sigma-
Aldrich, and were used without further purification. Melting points 
were found by capillary method and were uncorrected. Shimadzu 
Perkin Ekmer 8201 Pc infrared (IR) Spectrometer used in recording 
IR spectra (KBr pellets) and frequencies are expressed in cm−1. Bruker 
Avance II 400 nuclear magnetic resonance (NMR) spectrometer 
recorded NMR spectra. All spectra were obtained in CDCl3 and dimethyl 
sulfoxide (DMSO). Chemical shift values are reported as values in ppm 
relative to tetramethylsilane (δ=0) as internal standard. JEOL SX-
102/DA-6000 mass spectrometer recorded fast atom bombardment 
(FAB) mass spectra using Argon/Xenon (6 KV, 10 Ma) as the FAB 
gas. The elemental analysis has been obtained using Vairo elementar 
model, CHN analyzer, and the results were found to be within ±0.4%. 
Cata-R, Catalyst Systems 140-700 W microwave reactor was used for 
microwave synthesis.
Synthetic methods
General methods of synthesis of pyrazolines
A mixture of chalcone (0.01 mol), semicarbazide/thiosemicarbazide 
(0.01 mol) in ethanol (30 ml) in the presence of acetic acid (2 ml) 
was subjected to microwave irradiation for 7-8 minutes. With 
constant stirring, the reaction mixture was poured into cold water. 
The product thus obtained was recrystallized from suitable solvents. 
Ethyl acetate:chloroform (8:2) is the solvent system for thin layer 
chromatography. The same reaction mixture was refluxed for 12-14 hrs 
under conventional heating [3].
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i4.17093
Research Article
457
Asian J Pharm Clin Res, Vol 10, Issue 4, 2017, 456-459




Red crystals; m.p. 196-198°C; yield 76%; IR (cm−1): 3431.1 (aromatic 
CH str), 3097.8 (thiocarbamoyl NH str), 1646.8 (C=N str), 1594.7 (C=C str), 
1345.2 (C=S), 1385.0 (C-N), 544.7 (C-Br). 1H NMR (δ ppm): 3.991-4.044 
(dd, 1H, Ha), 3.212-3.214 (dd, 1H, Hb), 4.915-4.960 (dd, 1H, Hc), 
8.108-8.700 (m, 11H, Ar-H), 7.834-7.875 (d, 2H, NH2). Mass (m/z): (M+) 
460. Analytically calculated for C, 62.61; H, 3.94, found: C, 62.63; H, 3.91.
3-(4-chlorophenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazole-1-
carbothioamide (TP2)
Yellow crystals; m.p. 186-188°C; yield 77%; IR (cm−1): 3440.2 (aromatic 
CH str), 3077.7 (thiocarbamoyl NH str), 1635.6(C=N str), 1522.5 (C=C str), 
1336.7 (C=S), 1374.6 (C-N), 750.3 (C-Cl). 1H NMR (δ ppm): 4.012-4.043 
(dd, 1H, Ha), 3.423-3.456 (dd, 1H, Hb), 3.985-4.019 (dd, 1H, Hc), 
7.910-8.073 (m, 11H, Ar-H), 8.312-8.415 (d, 2H, NH2). Mass (m/z): (M+) 
416. Analytically calculated for C, 69.30; H, 4.36, found: C, 69.32; H, 4.38.
3-(4-fluorophenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazole-1-
carbothioamide (TP3)
Yellowish brown crystals; m.p. 169-171°C; yield 71%; IR (cm−1): 
3453.1 (aromatic CH str), 3025.5 (thiocarbamoyl NH str), 1643.6 
(C=N str), 1545 (C=C str), 1351.3 (C=S), 1379.2 (C-N), 1423 (C-F). 1H 
NMR (δ ppm): 4.657-4.683 (dd, 1H, Ha), 3.223-3.316 (dd, 1H, Hb), 
4.112-4.208 (dd, 1H, Hc), 7.471-7.802 (m, 11H, Ar-H), 8.413-8.482 (d, 
2H, NH2). Mass (m/z): (M+) 450. Analytically calculated for C, 72.16; H, 
4.54, found: C, 72.14; H, 4.52.
3-(4-aminophenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazole-1-
carbothioamide (TP4)
Brown crystals; m.p. 163-165°C; yield 65%; IR (cm−1): 3489.3 (aromatic 
CH str), 3031.8 (thiocarbamoyl NH str), 1641.4 (C=N str), 1521.1 (C=C str), 
1362.8 (C=S), 1396.8 (C-N), 1423 (C-NH2). 1H NMR (δ ppm): 4.611-4.664 
(dd, 1H, Ha), 3.167-3.190 (dd, 1H, Hb), 2.989-3.019 (dd, 1H, Hc), 
7.325-7.762 (m, 11H, Ar-H), 8.182-8.254 (d, 2H, NH2). Mass (m/z): (M+) 
396. Analytically calculated for C, 72.70; H, 5.08, found: C, 72.72; H, 5.05.
3-(4-nitrophenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazole-1-
carbothioamide (TP5)
Brownish yellow crystals; m.p. 163-165°C; yield 75%; IR (cm−1): 3329.3 
(aromatic CH str), 3026.2 (thiocarbamoyl NH str), 1653.7 (C=N str), 
1536.6 (C=C str), 1357.3 (C=S), 1394.3 (C-N), 1333.4 (C-NO2). 1H NMR 
(δ ppm): 3.981-4.011 (dd, 1H, Ha), 3.321-3.343 (dd, 1H, Hb), 2.788-
2.801 (dd, 1H, Hc), 7.02-7.661 (m, 11H, Ar-H), 8.231-8.267 (d, 2H, 
NH2). Mass (m/z): (M+) 426. Analytically calculated for C, 67.59; H, 4.25, 
found: C, 67.62; H, 4.23.
3-(4-chlorophenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazole-1-
carboxamide (SP1)
Red crystals; m.p. 127-129°C; yield 82 %; IR (KBr, cm−1): 3444.01 
(aromatic CH str), 3049.46, 3028.24 (carbamoyl NH2 str), 1622.13 
(C=N str), 1593.20 (C=C str), 1621.13 (C=O), 1384.89 (C-N), 732.95 (C-Cl). 
1H NMR (400 MHz, DMSO, δ/ppm): 3.71 (dd, 1H, HA), 3.93 (dd, 1H, HB), 
4.95 (dd, 1H, Hx), 7.37-7.99 (m, 11H, Ar-H); Mass (FAB), m/z: (M+) 399. 
Analytically calculated for C, 72.09; H, 4.54; found: C, 72.06; H, 4.52.
3-(4-bromophenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazole-1-
carboxamide (SP2)
Yellow crystals; m.p. 143-145°C; yield 72%; IR (KBr, cm−1): 3456.56 
(aromatic CH str), 3023.45, 3046.46 (carbamoyl NH2 str), 1625.73 
(C=N Str), 1556.29 (C=C Str), 1626.67 (C=O), 1356.45 (C-N), 656.45 
(C-Br). 1H NMR (400 MHz, DMSO, δ/ppm): 3.45 (dd, 1H, HA), 3.56 
(dd, 1H, HB), 3.97 (dd, 1H, Hx), 7.21-7.96 (m, 11H, Ar-H); analytically 
calculated for C, 64.88; H, 4.08; found: C, 64.85; H, 4.06.
3-(4-fluorophenyl)-5-(naphthalen-1-yl)-4,5-dihydro-1H-pyrazole-1-
carboxamide (SP3)
Red crystals; m.p. 169-171°C; yield 73 %; IR (KBr, cm−1): 3567.40 
(aromatic CH str), 3013.34, 3128.67 (carbamoyl NH2 str), 1626.23 
(C=N str), 1545.34 (C=C str), 16445.23 (C=O), 1373.38 (C-N), 1332.95 
(C-F). 1H NMR (400 MHz, DMSO, δ/ppm): 2.89 (dd, 1H, HA), 3.35 (dd, 
1H, HB), 3.78 (dd, 1H, Hx), 7.25-8.09 (m, 11H, Ar-H); mass (FAB), m/z: 




Red crystals; m.p. 168-169°C; yield 80%; IR (KBr, cm−1): 3542.41 
(aromatic CH str), 3056.34, 3056.67 (carbamoyl NH2 str), 1667.56 
(C=N Str), 1578.56 (C=C Str), 1634.23 (C=O), 1386.44 (C-N), 1332.95 
(C-NH2). 1H NMR (400 MHz, DMSO, δ/ppm): 3.74 (dd, 1H, HA), 3.98 (dd, 
1H, HB), 4.36 (dd, 1H, Hx), 7.78-8.47 (m, 11H, Ar-H); Mass (FAB), m/z: 




Brown crystals; m.p. 172-175°C; yield 83%; IR (KBr, cm−1): 3448.43 
(aromatic CH str), 3032.14, 3064.32 (carbamoyl NH2 str), 1628.23 
(C=N str), 1585.34 (C=C str), 1632.33 (C=O), 1356.67 (C-N), 3209.43 
(C-OH). 1H NMR (400 MHz, DMSO, δ/ppm): 3.25 (dd, 1H, HA), 3.47 
(dd, 1H, HB), 3.95 (dd, 1H, Hx), 7.22-7.81 (m, 11H, Ar-H); Mass 
(FAB), m/z: (M+) 381; analytically calculated for C, 75.57; H, 5.02; 
found: C, 75.58; H, 5.00.
In silico studies
Physicochemical properties
Physiochemical properties and the presence of various pharmacophoric 
features, influence the behaviors of molecules in a living organism, 
including bioavailability. Good intestinal absorption, molecular 
flexibility (measured by the number of rotatable bonds), low polar 
surface area or total hydrogen bond count (sum of donors and 
acceptors), are important predictors of good oral bioavailability [8]. 
Thus, to achieve good oral drugs, we have investigated a series of 
pyrazoline derivatives bearing a anthracenyl moiety for the prediction 
of their molecular properties, Lipinski’s “Rule of Five” [9] and drug 
likeness properties. High oral bioavailability is an important factor for 
the development of bioactive molecules as therapeutic agents.
Rule of Five properties
Lipinski [9] used various molecular properties in formulating his “Rule 
of Five.” The rule states that most molecules with good membrane 
permeability have log P ≤5, MW≤500, the number of hydrogen bond 
acceptors ≤10, and the number of hydrogen bond donors ≤5. The rule is 
widely used as a filter for drug-like properties. A compound that fulfills 
at least three out of the four criteria is said to adhere to “Lipinski’s Rule 
of Five.” A poor permeation or absorption is more likely when there are 
more than five H-bond donors and ten H-bond acceptors [10].
The compounds that were drawn using ChemDraw software were 
initially screened for Lipinski’s rule of 5 using Molinspiration server.
Biological activities
Evaluation of antidiabetic activity [11]
The compounds were tested for in vitro alpha-amylase inhibition assay. 
Preincubation of starch azure (substrate) and TrisHCL buffer was done 
at 37°C for 5 minutes. To this mixture, the test sample along with porcine 
pancreatic amylase in TrisHCL buffer was added and then incubated for 
10 minutes at 37°C. The absorbance was measured at 595 nm using 
microplate reader BMG, Germany. The inhibitory concentration was 
calculated and reported.
Evaluation of antioxidant activity
2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity
The stable radical DPPH was used as the reagent in this 
spectrophotometric assay [12]. 3 ml of 0.1 mM solution of DPPH and 
1 ml of the compounds bearing different concentrations (10-200 μM) 
458
Asian J Pharm Clin Res, Vol 10, Issue 4, 2017, 456-459
 James et al. 
was mixed was kept in the dark for 30 minutes. It was incubated for 
30 minutes at room temperature, and the absorbance was read against 
blank at 517 nm.
Nitric oxide (NO) free radical scavenging method
NO radicals were generated from sodium nitroprusside. 1 ml of sodium 
nitroprusside (10 mM) and 1.5 ml of phosphate-buffered saline 
(0.2 M, pH 7.4) were added to the various test concentrations (10-200 μM). 
These mixtures were incubated for 150 minutes at 25°C. Moreover, 1 ml of 
Griess reagent was added, and absorbance was read against 546 nm [13].
For both antioxidant determination methods, the percentage of 
inhibition was computed from the following equation:
Inhibition level  






Cyclization of chalcone with thiosemicarbazide/semicarbazide in 
conventional and microwave methods has been described in the 
Scheme 1. Comparison of conventional and microwave techniques, in 
terms of time and yields, have been described in Table 1. Spectral and 
elemental analysis data confirmed the structure of the compounds.
In IR spectra an absorption band in TP1 afforded pyrazoline C-N 
stretching 1646.8 cm−1 and C=S bands at 1345.2 cm−1. In 1H NMR 
spectra of TP1, the CH2 protons of the pyrazoline ring resonated as 
a pair of doublets of doublets at 3.991 ppm (HA), 3.212 ppm (HB). 
The CH (Hx) proton appeared as a doublet of doublets at 4.915 ppm. 
This confirmed the cyclization of chalcones to 2-pyrazolines. Mass 
spectra of compounds were collected and the molecular ion peak was 
found correct according to the molecular formula.
Physicochemical properties
The analogs possessed desired physicochemical properties with no 
violations from the standard ranges and are tabulated in Table 2. The 
number of the rotatable bond must be <10. Drugs that penetrate central 
nervous system should have lower polar surface areas <140 than other 
kinds of molecules. The results showed that all the compounds have a 
promising oral bioavailability.
Rule of five properties
Based on the experimental values, it was inferred that all the 
compounds successfully satisfied all the parameters of Lipinski’s 
Rule of Five. Compounds with log P values <5, mean that they can 
readily get pass  ester/phosphate groups in skin membranes. The 
results obtained are given in Table 2. The calculated values of log P 
for the derivatives ranged from 2.72 to 4.7. The lipophilic aptitude of a 
compound increases with the increasing log P. The C log P values of all 
the compounds show variation which can be attributed to the presence 
and position of different substituents on the phenyl ring. The series 
under investigation has not only the most of the compounds possessing 
less number of hydrogen bond donors (<5) but also does possess 
considerable number of acceptors (<10).
All the pyrazolines tested for antidiabetic and antioxidant studies 
showed promising activity when compared with the standard. Among 
that, compounds TP1 and TP3 showed anti-diabetic activity equivalent 
to standard acarbose as given in Table 3.
Table 4 exhibited the radical scavenging activity results in DPPH and 
NO methods, stating that compounds TP1 and TP5 proved to as good 
scavengers from both methods.
CONCLUSION
The present study has achieved the efficient synthesis of pyrazoline 
bearing a naphthyl moiety and examined their preliminary in vitro 
antidiabetic and antioxidant activities. The molecular properties were 
predicted, which showed that these active compounds can be used 
as templates for development of new drugs. In addition, it was found 
Scheme 1: Synthesis of pyrazolines
Table 1: Reaction time and yield of conventionally and 





Time (hrs) Yield (%) Time (minutes) Yield (%)
Pyrazolines 12-14 54-73 7-8 65-83
Table 2: Physicochemical properties of pyrazoline derivatives
Compound  
code
tPSA nrobs Molecular 
weight
Log P nONs nOHNHs
TP1 41.62 3 410.33 4.7 3 2
TP2 41.62 3 365.88 4.62 3 2
TP3 41.62 3 349.42 4.23 4 4
TP4 67.64 3 346.45 3.27 4 3
TP5 61.85 3 347.43 3.69 4 3
SP1 58.69 2 349.81 4.07 4 2
SP2 58.69 2 394.26 4.34 4 2
SP3 58.69 2 333.36 3.67 4 2
SP4 84.75 2 330.38 2.71 5 4
SP5 96.94 2 331.37 3.13 5 3
PSA: Polar surface area













IC50: Inhibitory concentration 50%
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that all the compounds followed Lipinski’s Rule of Five. Thus, the 
idea of appending the naphthyl moiety to the pyrazoline nucleus so 
as to combine the beneficial effects in a single structure proved to be 
successful. In conclusion, the present study showed that synthesized 
compounds can be used as template for future development through 
modification and derivatization.
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